89 related articles for article (PubMed ID: 11126359)
21. Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma.
Schram AM; Jonsson P; Drilon A; Bale TA; Hechtman JF; Benayed R; Hanusch B; Young RJ; Grommes C; Ku N; Kaley T; Hyman DM; Taylor BS
JCO Precis Oncol; 2018; 2():. PubMed ID: 31218270
[No Abstract] [Full Text] [Related]
22. Antitumor activity of larotrectinib in tumors harboring
Ricciuti B; Genova C; Crinò L; Libra M; Leonardi GC
Onco Targets Ther; 2019; 12():3171-3179. PubMed ID: 31118670
[TBL] [Abstract][Full Text] [Related]
23. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A; Laetsch TW; Kummar S; DuBois SG; Lassen UN; Demetri GD; Nathenson M; Doebele RC; Farago AF; Pappo AS; Turpin B; Dowlati A; Brose MS; Mascarenhas L; Federman N; Berlin J; El-Deiry WS; Baik C; Deeken J; Boni V; Nagasubramanian R; Taylor M; Rudzinski ER; Meric-Bernstam F; Sohal DPS; Ma PC; Raez LE; Hechtman JF; Benayed R; Ladanyi M; Tuch BB; Ebata K; Cruickshank S; Ku NC; Cox MC; Hawkins DS; Hong DS; Hyman DM
N Engl J Med; 2018 Feb; 378(8):731-739. PubMed ID: 29466156
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.
Greco A; Auletta L; Orlandella FM; Iervolino PLC; Klain M; Salvatore G; Mancini M
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258188
[TBL] [Abstract][Full Text] [Related]
26. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.
Ricciuti B; Brambilla M; Metro G; Baglivo S; Matocci R; Pirro M; Chiari R
Med Oncol; 2017 Jun; 34(6):105. PubMed ID: 28444624
[TBL] [Abstract][Full Text] [Related]
27. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma.
Vuong HG; Duong UN; Altibi AM; Ngo HT; Pham TQ; Tran HM; Gandolfi G; Hassell L
Endocr Connect; 2017 Apr; 6(3):R8-R17. PubMed ID: 28219937
[TBL] [Abstract][Full Text] [Related]
28. ProNGF is a potential diagnostic biomarker for thyroid cancer.
Faulkner S; Roselli S; Demont Y; Pundavela J; Choquet G; Leissner P; Oldmeadow C; Attia J; Walker MM; Hondermarck H
Oncotarget; 2016 May; 7(19):28488-97. PubMed ID: 27074571
[TBL] [Abstract][Full Text] [Related]
29. Mouse models of thyroid cancer: A 2015 update.
Kirschner LS; Qamri Z; Kari S; Ashtekar A
Mol Cell Endocrinol; 2016 Feb; 421():18-27. PubMed ID: 26123589
[TBL] [Abstract][Full Text] [Related]
30. Neuropilin-2 Is a Newly Identified Target of PAX8 in Thyroid Cells.
Lucci V; Di Palma T; Zannini M
PLoS One; 2015; 10(6):e0128315. PubMed ID: 26030152
[TBL] [Abstract][Full Text] [Related]
31. TRKing down an old oncogene in a new era of targeted therapy.
Vaishnavi A; Le AT; Doebele RC
Cancer Discov; 2015 Jan; 5(1):25-34. PubMed ID: 25527197
[TBL] [Abstract][Full Text] [Related]
32. Modulation of sodium iodide symporter in thyroid cancer.
Lakshmanan A; Scarberry D; Shen DH; Jhiang SM
Horm Cancer; 2014 Dec; 5(6):363-73. PubMed ID: 25234361
[TBL] [Abstract][Full Text] [Related]
33. Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Mancini M; Greco A; Salvatore G; Liuzzi R; Di Maro G; Vergara E; Chiappetta G; Pasquinelli R; Brunetti A; Salvatore M
BMC Med Imaging; 2013 Sep; 13():31. PubMed ID: 24028408
[TBL] [Abstract][Full Text] [Related]
34. Mouse models of follicular and papillary thyroid cancer progression.
Russo MA; Antico Arciuch VG; Di Cristofano A
Front Endocrinol (Lausanne); 2011; 2():119. PubMed ID: 22654848
[TBL] [Abstract][Full Text] [Related]
35. An essential role for Pax8 in the transcriptional regulation of cadherin-16 in thyroid cells.
de Cristofaro T; Di Palma T; Fichera I; Lucci V; Parrillo L; De Felice M; Zannini M
Mol Endocrinol; 2012 Jan; 26(1):67-78. PubMed ID: 22135066
[TBL] [Abstract][Full Text] [Related]
36. Lessons from mouse models of thyroid cancer.
Kim CS; Zhu X
Thyroid; 2009 Dec; 19(12):1317-31. PubMed ID: 20001715
[TBL] [Abstract][Full Text] [Related]
37. Modeling thyroid cancer in the mouse.
Zhu XG; Cheng SY
Horm Metab Res; 2009 Jun; 41(6):488-99. PubMed ID: 19358084
[TBL] [Abstract][Full Text] [Related]
38. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
[TBL] [Abstract][Full Text] [Related]
39. UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas.
Pallante P; Berlingieri MT; Troncone G; Kruhoffer M; Orntoft TF; Viglietto G; Caleo A; Migliaccio I; Decaussin-Petrucci M; Santoro M; Palombini L; Fusco A
Br J Cancer; 2005 Aug; 93(4):464-71. PubMed ID: 16106252
[TBL] [Abstract][Full Text] [Related]
40. Expression of NGF family and their receptors in gastric carcinoma: a cDNA microarray study.
Du JJ; Dou KF; Peng SY; Qian BZ; Xiao HS; Liu F; Wang WZ; Guan WX; Gao ZQ; Liu YB; Han ZG
World J Gastroenterol; 2003 Jul; 9(7):1431-4. PubMed ID: 12854135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
